Table 4.
Overall cohort: Crude and cumulative incidence of cardiac events (fatal vs. life-threatening vs. no cardiac event) according to demographic, clinical, and biological characteristics of patients at diagnosis.
| No Cardiac Event | p-Value * | Non-Life-Threatening | Life-Threatening | Fatal | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | N (%) | Crude Incidence N (%) |
Cumulative Incidence | Crude Incidence N (%) |
Cumulative Incidence | Crude Incidence N (%) |
Cumulative Incidence | |||||||
| At 6 months, % | At Last FU, % | p | At 6 months, % | At Last FU, % | p | At 6 months, % | At Last FU, % | p | ||||||
| N | 218 (41.5) | 261 (49.7) | 40 | 53.1 | 27 (5.1) | 4.1 | 6.4 | 19 (3.6) | 2 | 6.7 | ||||
| Age | 218 | 261 | 27 | 19 | ||||||||||
| <65 years | 128 (48.5) | <0.001 | 108 (40.9) | 32.9 | 43.8 | <0.001 | 19 (7.2) | 4.7 | 8.2 | 0.11 | 9 (3.4) | 1.6 | 5.9 | 0.25 |
| ≥65 years | 90 (34.5) | 153 (58.6) | 47.2 | 62.9 | 8 (3.1) | 3.5 | 3.5 | 10 (3.8) | 2.5 | 6.8 | ||||
| Relevant cardiologic antecedents | 218 | 261 | 27 | 19 | ||||||||||
| No | 202 (44.7) | <0.001 | 215 (47.6) | 37.9 | 50.4 | 0.001 | 25 (5.5) | 4.4 | 6.6 | 0.45 | 10 (2.2) | 1.2 | 4.9 | <0.001 |
| Yes | 16 (21.9) | 46 (63) | 53.4 | 71.7 | 2 (2.7) | 1.9 | 4 | 9 (12.3) | 7.2 | 20.1 | ||||
| Previous anthracycline treatment | 218 | 261 | 27 | 19 | ||||||||||
| No | 207 (42.1) | 0.6 | 242 (49.2) | 39.5 | 52.3 | 0.33 | 26 (5.3) | 4.1 | 6.5 | 0.7 | 17 (3.5) | 1.7 | 6.5 | 0.22 |
| Yes | 11 (33.3) | 19 (57.6) | 47.5 | 58.8 | 1 (3) | 4 | 4 | 2 (6.1) | 6.7 | 6.7 | ||||
| ECOG at diagnosis | 218 | 261 | 27 | 19 | ||||||||||
| <2 | 173 (41.4) | 0.99 | 209 (50) | 39.6 | 53.3 | 0.6 | 21 (5) | 3.8 | 6.1 | 0.56 | 15 (3.6) | 2 | 6.7 | 0.56 |
| ≥2 | 45 (42.1) | 52 (48.6) | 41.3 | 52.6 | 6 (5.6) | 5.5 | 7.5 | 4 (3.7) | 1.9 | 5.5 | ||||
| FLT3-ITD status | 197 | 243 | 26 | 19 | ||||||||||
| Negative | 161 (39.5) | 0.55 | 209 (51.2) | 40.3 | 55.3 | 0.34 | 21 (5.2) | 4.2 | 6.1 | 0.63 | 17 (4.2) | 2.3 | 7.8 | 0.53 |
| Positive | 36 (46.8) | 34 (44.2) | 38.2 | 45.5 | 5 (6.5) | 5.6 | 7.3 | 2 (2.6) | 1.4 | 3.1 | ||||
| Treatment chemotherapy | 218 | 261 | 27 | 19 | ||||||||||
| Intensive | 125 (43.9) | 0.07 | 130 (45.6) | 37.6 | 48.8 | 0.025 | 20 (7) | 4.8 | 8.3 | 0.088 | 10 (3.5) | 1.9 | 6.3 | 0.37 |
| Non-intensive | 93 (38.8) | 131 (54.6) | 42.7 | 58.1 | 7 (2.9) | 3.2 | 3.2 | 9 (3.8) | 2.2 | 6.8 | ||||
| Inclusion in clinical trial | 218 | 261 | 27 | 19 | ||||||||||
| No | 140 (47.8) | <0.001 | 125 (42.7) | 32.8 | 45.4 | <0.001 | 20 (6.8) | 5 | 8 | 0.096 | 8 (2.7) | 1.1 | 5.4 | 0.06 |
| Yes | 78 (33.6) | 136 (58.6) | 49.2 | 63.5 | 7 (3) | 2.9 | 3.5 | 11 (4.7) | 3.2 | 6.5 | ||||
| Use of FLT3 inhibitors | 218 | 0.71 | 261 | 27 | 19 | |||||||||
| No | 204 (41.9) | 239 (49.1) | 38.9 | 52.3 | 0.19 | 26 (5.3) | 4.2 | 6.7 | 0.43 | 18 (3.7) | 2.2 | 4.8 | 0.76 | |
| Yes | 14 (36.8) | 22 (57.9) | 53 | 58.8 | 1 (2.6) | 2.7 | 2.7 | 1 (2.6) | 0 | 3.1 | ||||
* This p-value compares the crude incidence between the four groups. FU: follow-up.